Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Veracyte Inc (VCYT)

Veracyte Inc (VCYT)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 3,386,460
  • Shares Outstanding, K 79,049
  • Annual Sales, $ 445,760 K
  • Annual Income, $ 24,140 K
  • EBIT $ 22 M
  • EBITDA $ 46 M
  • 60-Month Beta 1.83
  • Price/Sales 7.49
  • Price/Cash Flow 40.72
  • Price/Book 2.64

Options Overview Details

View History
  • Implied Volatility 61.06% (-10.31%)
  • Historical Volatility 88.60%
  • IV Percentile 24%
  • IV Rank 28.08%
  • IV High 109.12% on 04/14/25
  • IV Low 42.30% on 08/13/25
  • Expected Move (DTE 4) 3.88 (8.96%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 16
  • Volume Avg (30-Day) 96
  • Put/Call OI Ratio 0.11
  • Today's Open Interest 3,133
  • Open Int (30-Day) 2,737
  • Expected Range 39.47 to 47.23

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 0.27
  • Number of Estimates 4
  • High Estimate 0.28
  • Low Estimate 0.26
  • Prior Year 0.24
  • Growth Rate Est. (year over year) +12.50%

Price Performance

See More
Period Period Low Period High Performance
1-Month
37.98 +14.11%
on 11/18/25
50.71 -14.53%
on 11/25/25
+3.99 (+10.14%)
since 11/14/25
3-Month
31.33 +38.34%
on 09/16/25
50.71 -14.53%
on 11/25/25
+11.47 (+35.99%)
since 09/15/25
52-Week
22.61 +91.69%
on 07/18/25
50.71 -14.53%
on 11/25/25
+0.12 (+0.28%)
since 12/13/24

Most Recent Stories

More News
Veracyte to Participate in Upcoming Investor Conferences

Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the following investor conferences. ...

VCYT : 43.58 (+1.73%)
Veracyte: Q3 Earnings Snapshot

Veracyte: Q3 Earnings Snapshot

VCYT : 43.58 (+1.73%)
Veracyte Announces Third Quarter 2025 Financial Results

Grew total revenue to $131.9 million and testing revenue to $127.8 million, representing increases of 14% and 17% year-over-year, respectively Conference call and webcast...

VCYT : 43.58 (+1.73%)
Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing

Landmark studies leverage Afirma GRID whole transcriptome-derived data to identify molecular classifiers and signatures differentiating thyroid cancer risk groups

VCYT : 43.58 (+1.73%)
Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025

Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the third quarter of 2025 after the close of market on Tuesday, November...

VCYT : 43.58 (+1.73%)
Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer

Findings from the first prospective validation trial for biomarker presented at ASTRO 2025

VCYT : 43.58 (+1.73%)
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

USA News Group News Commentary

VCYT : 43.58 (+1.73%)
QURE : 20.39 (+4.51%)
HUM : 274.60 (+2.29%)
AVAI : 0.3199 (-3.03%)
EDIT : 2.44 (-3.56%)
Healthcare Innovation Accelerates as Four Converging Forces Drive Early Intervention Focus

/CNW/ -- America's aging demographics are creating unprecedented demand for precision healthcare solutions, with population projections showing nearly one in...

VCYT : 43.58 (+1.73%)
HUM : 274.60 (+2.29%)
QURE : 20.39 (+4.51%)
AVAI : 0.3199 (-3.03%)
EDIT : 2.44 (-3.56%)
Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025

Findings are among nine Decipher-focused abstracts being presented at annual conference

VCYT : 43.58 (+1.73%)
Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting

Studies leverage company’s Afirma Genomic Resource for Intelligent Discovery (GRID), world’s largest molecular database for thyroid nodules

VCYT : 43.58 (+1.73%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 50%. The market is indicating support for a bullish trend.

See More Share

Business Summary

Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also...

See More

Key Turning Points

3rd Resistance Point 45.50
2nd Resistance Point 44.45
1st Resistance Point 43.65
Last Price 43.58
1st Support Level 41.79
2nd Support Level 40.74
3rd Support Level 39.94

See More

52-Week High 50.71
Last Price 43.58
Fibonacci 61.8% 39.98
Fibonacci 50% 36.66
Fibonacci 38.2% 33.34
52-Week Low 22.61

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar